Piramal Pharma Limited has recently informed exchanges that the company has begun its sustainability journey as the Science Based Targets Initiative (SBTi) officially validated the company’s near-term greenhouse gas (GHG) emission reduction targets. This validation is consistent with Piramal Pharma’s fundamental mission of ‘Doing Well and Doing Good,’ which drives its business strategies and supports the company’s commitment to achieving consistent, measurable progress toward a more sustainable future.
Piramal Pharma Limited is committed to reducing absolute scope 1 and 2 GHG emissions by 42% by FY2030 compared to the FY2022 base year. The company has also committed to reducing absolute scope 3 GHG emissions from acquired goods and services, fuel and energy-related operations, upstream transportation and distribution, and usage of sold products by 25% during the same time period.
Piramal Pharma is the third global pharmaceutical company in India to get approval from the SBTi.
